An Open Label Phase II Study to Evaluate Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 20 Jan 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Neratinib (Primary) ; Capecitabine; Paclitaxel; Trastuzumab; Trastuzumab; Trastuzumab emtansine; Vinorelbine
Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer; Meningeal carcinomatosis
Focus Therapeutic Use
Acronyms NeraBrain

28 Nov 2021 Planned number of patients changed from 104 to 125.
24 Nov 2021 Planned End Date changed from 15 Jul 2025 to 24 Nov 2021.
24 Nov 2021 Planned primary completion date changed from 15 Jan 2024 to 24 Nov 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com